BPC-157 Research Overview: What the Science Shows

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is a partial sequence derived from the gastric protein BPC (body protection compound). Unlike many research peptides, BPC-157 does not occur naturally in isolation — it is a synthesised research compound.

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

CAS: 137525-51-0

Molecular Weight: 1419.53 Da

Formula: C₆₂H₉₈N₁₆O₂₂

BPC-157 was first characterised and studied by a research group at the University of Zagreb (Croatia), led by Professor Predrag Sikiric. Their work, spanning from the early 1990s to the present, forms the foundation of published BPC-157 research. The peptide has since been studied by independent groups across Europe, Asia, and the United States.

Molecular Structure and Stability

The 15-amino acid sequence of BPC-157 gives it a distinctive structural profile. The high proportion of proline residues (five in the sequence) contributes to its conformational rigidity, which is associated with the compound's notable stability characteristics observed in preclinical settings — including resistance to degradation in gastric acid environments in animal models.

In research formulation, BPC-157 is typically supplied as a lyophilised (freeze-dried) powder. This preserves stability during storage and distribution. The lyophilised form remains stable at −20°C for up to two years, and for weeks at 2–8°C once reconstituted with bacteriostatic water. These stability properties make it practical to work with in laboratory settings compared to many other research peptides.

Key Research Areas

Does BPC-157 Promote Angiogenesis and Vascular Repair?

Key finding: BPC-157 promotes angiogenesis in preclinical wound healing models through upregulation of VEGFR2 (vascular endothelial growth factor receptor 2) and FAK-paxillin signalling pathways, facilitating new blood vessel formation that supports tissue repair and recovery in research models.

Multiple preclinical studies have investigated BPC-157's effects on angiogenesis — the formation of new blood vessels from existing vasculature. Research has identified involvement of vascular endothelial growth factor receptor 2 (VEGFR2) and focal adhesion kinase-paxillin (FAK-paxillin) signalling pathways.

In wound healing models, the upregulation of VEGFR2 is proposed to accelerate neovascularisation, which is thought to underpin observed improvements in tissue repair timelines in rodent studies. The compound has been studied in both in-vitro cell migration assays and in-vivo surgical wound models.

Does BPC-157 Support Gut Health and Gastrointestinal Healing?

Key finding: BPC-157 has one of the largest published preclinical research bodies in gastrointestinal science for any synthetic peptide, with studies demonstrating protective effects across gastric ulcer, intestinal anastomosis, and inflammatory bowel models via nitric oxide modulation and VEGFR2 pathway activation.

BPC-157 has one of the largest published preclinical research bodies in gastrointestinal (GI) science for any synthetic peptide. Rodent studies have examined its effects across a wide range of GI contexts:

• •Gastric ulcer models: Studies published in the *Journal of Physiology and Pharmacology* and *European Journal of Pharmacology* report accelerated healing in cysteamine-induced and ethanol-induced ulcer models
• •Intestinal anastomosis: Research has examined BPC-157 in bowel resection and re-anastomosis models, assessing healing integrity and dehiscence rates
• •Inflammatory bowel models: Acetic acid and TNBS-induced colitis models in rodents have been used to study BPC-157's effects on mucosal integrity and inflammatory markers
• •Gut-brain axis research: Given its derivation from the gastric BPC protein, researchers have explored signalling connections between GI administration and central nervous system endpoints

Proposed mechanisms in GI research include nitric oxide (NO) pathway modulation, prostaglandin involvement, and direct cytoprotective effects on mucosal cells.

What Does BPC-157 Research Show for Tendon and Ligament Healing?

Several rodent studies have examined BPC-157 in musculoskeletal models — particularly tendon-to-bone healing. Chang et al. (2011) published data on tendon outgrowth, cell survival, and cell migration in a rat Achilles tendon model, observing differences in tendon cell proliferation rates between treated and control groups.

Additional studies have looked at:

• •Collagen synthesis markers (Type I and Type III collagen ratios) in healing tendon tissue
• •Fibroblast activity and morphology in treated versus untreated wound sites
• •Bone-to-tendon interface healing in surgically created defect models
• •Ligament injury models examining structural integrity restoration

The FAK-paxillin pathway implicated in angiogenesis research is also considered relevant in musculoskeletal healing contexts, as it plays a role in cell adhesion and migration.

Does BPC-157 Affect the Brain and Nervous System?

Preclinical studies have investigated BPC-157 in central nervous system (CNS) models, with a focus on dopaminergic and serotonergic neurotransmitter systems. Research has examined:

• •Dopaminergic pathway interactions: Studies have looked at BPC-157 in models of dopamine dysregulation, including rotational behaviour studies in 6-OHDA lesioned rats
• •Serotonergic effects: Interactions with serotonin receptor subtypes have been investigated in stress and behavioural models
• •Brain-gut axis: The 2016 review by Sikiric et al. in *Current Neuropharmacology* comprehensively covered theoretical and practical implications of the brain-gut connection for BPC-157 research
• •Neuroprotective models: Some studies have used excitotoxicity and ischaemia models to study BPC-157's effects on neuronal survival markers

How Does BPC-157 Interact With Inflammatory Pathways?

BPC-157 research has explored interactions with systemic and local inflammatory pathways across multiple rodent models. Studies published in the *European Journal of Pharmacology* have investigated NF-κB signalling modulation, prostaglandin E2 (PGE2) pathway involvement, and shifts in pro-inflammatory cytokine profiles including TNF-α, IL-6, and IL-1β in acute injury and colitis models. In these preclinical models, BPC-157 administration was associated with downregulation of several key pro-inflammatory markers compared to untreated controls. The proposed mechanism involves interaction with the nitric oxide pathway and direct modulation of upstream inflammatory transcription factor activity. The anti-inflammatory research profile complements BPC-157's angiogenic and tissue repair mechanisms, as reducing excessive inflammation is a critical step in productive healing. Sikiric et al. (2016, *Current Neuropharmacology*) provided a comprehensive theoretical framework connecting these anti-inflammatory effects to the brain-gut axis. These findings are from preclinical models and have not been validated in human clinical trials.

How Does BPC-157 Compare to TB-500 for Tissue Research?

BPC-157 is frequently compared to TB-500 (thymosin beta-4 fragment, Ac-LKKTETQ) as both are studied in tissue repair contexts. However, they have distinct mechanisms and research applications:

Research protocols often combine both compounds to explore complementary mechanisms in musculoskeletal repair models. Our BPC-157 + TB-500 Blend 10mg provides 5mg of each in a single vial for this research design.

Research Literature Summary

Published research on BPC-157 spans more than 30 years, with the majority of studies conducted in rodent (rat and mouse) in-vivo models, supplemented by in-vitro cell culture work. The University of Zagreb research group has published over 100 papers on BPC-157 across multiple journals.

Key publication venues include:

• •*Journal of Physiology and Pharmacology*
• •*European Journal of Pharmacology*
• •*Current Neuropharmacology*
• •*CNS & Neurological Disorders Drug Targets*
• •*Journal of Applied Physiology*

The compound remains an active area of preclinical research. As of 2026, no large-scale human clinical trial data has been published, which remains the primary limitation of the current evidence base.

Research Formulation Notes

For researchers working with BPC-157, formulation considerations include:

• •Reconstitution: Use bacteriostatic water (BAC water) at 1–2mL per 10mg vial as a standard starting point. See our Reconstitution Guide for detailed protocol steps
• •Storage post-reconstitution: Refrigerate at 2–8°C; use within 4 weeks
• •Concentration calculation: Use our Peptide Calculator Guide to work out concentration per volume
• •Research purity standard: Independent HPLC verification at 99%+ is the accepted quality threshold for research-grade peptides. See our HPLC Purity Guide for how to read a COA

Important Research Limitations

All BPC-157 research must be conducted in accordance with applicable ethical guidelines and institutional regulations. This compound is for in-vitro research and laboratory use only.

Purchasing Research-Grade BPC-157 in Australia

Our BPC-157 10mg is independently verified at 99.2% HPLC purity with full COA documentation including mass spectrometry identity confirmation and sterility screening. Manufactured under GMP-certified conditions and dispatched from our Australian warehouse with next-day dispatch on weekday orders placed before 9PM AEST.

For combination research designs, our BPC-157 + TB-500 Blend 10mg provides 5mg of each compound in a single lyophilised vial.

Disclaimer: All information is based on published preclinical research literature and is for educational purposes only. Not medical advice. All research must be conducted in accordance with applicable laws and regulations.